February 2012 Issue of MMM
February 2012 issue
A body of evidence suggests that gamification might change the world
Marc Iskowitz on how Shire's disease-awareness campaign engaged untreated Gen Y-ers, and why it's time for more patient-education efforts like it. Plus: See patient advocates ...
The Medical Advertising Hall of Fame's three new members have had exceptional lives and careers. We look back at their achievements
Pharma firms are partnering with managed care companies to find drug evidence and improve outcomes. Can this strategy provide the proof payers demand before giving ...
The MM&M Awards 2012 program is open for business.
Fred Wilkinson's "second tour of duty" at Watson includes global expansion, R&D investing and launching branded and generic products
New cardiovascular treatments are gaining FDA approval as massive brands lose patent protection. Noah Pines on the potential of these new entrants to replace that ...
A survey shows that many leaders think "the current commercial pharmaceutical model is broken"
The Materni T21 test has been found sensitve for discovering Down Syndrome in over 99% of cases
News of WebMD's planned sale—since aborted—surprised many observers.
Novartis will eliminate 1,630 sales rep jobs and 330 headquarters marketing jobs as its hypertension franchise faces the impending loss of Diovan patent exclusivity and ...
Takeda said it will slash its global workforce by around 2,800 jobs—700 in the US, the rest in Europe—as it absorbs Nycomed and moves toward ...
News on Standard Research, Human Genome Sciences, ImpactRx and DCA
Med Ed Report
A quarter of physicians in a recent survey cited a decrease in CME quality as commercial support has dropped.
Damon Marquis wants to make one thing clear: CME is not the only important form of medical education.
Ppatient advocacy groups and professional medical associations producing CME, though they may not be "covered recipients" under the Sunshine Act, could still be impacted
News on Us Healthconnect, Medical Insight, PCI and LLC
WebMD's non-sale was the big story in digital health media last month, but the buzz in the space is all around software-as-a-service firms, says media ...
A systematic review of Roche's antiviral drug Tamiflu appearing in last month's Cochrane Library has led to questions about the data's efficacy, as well as ...
The New England Journal of Medicine celebrates its 200th aniversary by producing a series of review articles and perspective pieces by established authors
News on Archives of Neurology, Science, Journal of Pharmacokinetics and Pharmacodynamics and The Ocular Surface
For media buyers, 2012 means the "quadrennial" cyclical driver. The Summer Olympics and European Soccer Championship are expected to boost advertising. Will we see more ...
WebMD scrapped plans for a possible sale and announced that president and CEO Wayne Gattinella is stepping down after 11 years in that role.
Healthline Networks has secured a deal with Drugs.com giving it exclusive rights to sell consumer ads on the site
Merck's Global Health Innovation Fund (GHIF) is investing up to $17 million in Physicians Interactive
News on Quintiles, Pfizer, Elsevier, Wolters Kluwer and Doctors.net.uk
GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands ...
Johnson & Johnson is promoting the head of its global vision-care business to serve as its marketing and PR chief
Spiriva's "Controlling the Elephant" campaign is one of the most brilliant we've seen in ages.
The pace of deal-making in marketing research has quickened, as firms prepare for new regulation that could affect HCPs' survey participation.
Privately held inVentiv Health is acquiring two of SDI Health's audit businesses worth under $15 million, firms said.
CDM Group promoted Kyle Barich to president of CDM New York and named Lori Klein, PharmD, director of client services and Chris Palmer and Ben ...
Indie medical advertising agency Dudnyk opened a southern California office, citing unmet need among the thousand or so biotech firms in the area.
News on Heartbeat West, Ogilvy, GCI Health and Green Room Public Relations
Political interference in FDA's scientific decisions is growing, well-hidden phenomenon
Sen. Dan Coats (R-IN) has introduced a bill to clarify and reform FDA's mission in order to keep jobs from going overseas.
"Emerging sponsors" or companies that have never had an approved application to market a drug are wreaking havoc on review activities at FDA's drugs center, ...
Siri's first step towards board certification could be creating a health-specific data engine
The horizon is changing and increasingly challenging. This can be a good and promising thing
Six useful Apple IOS apps that likely met with little resistance from the legal team
At Work With
Ed Mitzen, Partner, FingerPaint Marketing
Name That Brand
Harnessing the power of digital and social media to maximize the doctor/patient relationship
- The MM&M Weekly News Quiz: September 4
- Five things for pharma marketers to know: Friday, September 4
- New data expected at lung-cancer conference on experimental drug combos
- Sandoz: Zarxio marketing to be similar to a branded-drug launch
- Five things for pharma marketers to know: Thursday, September 3, 2015
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.